Trial Profile
Efficacy of Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve Measurements
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Regadenoson (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 27 Aug 2018 New trial record
- 19 Aug 2018 Primary endpoint (Comparing Measurement of Fractional Flow Reserve (FFR)) has not been met, according to results published in the Clinical Cardiology.
- 19 Aug 2018 Results published in the Clinical Cardiology